ConjuChem
 |
| Company type | Public (TSX has Delisted this Stock) |
|---|---|
| Industry | Biotechnology |
| Headquarters | , |
Key people | Mark Perrin |
| Products | Drug Affinity Construct (DAC) and Preformed Conjugate-Drug Affinity Construct (PC-DAC) |
Number of employees | 44[citation needed][needs update] |
| Website | www.conjuchem.com |
ConjuChem Biotechnologies Inc. is a medical biotechnology company located in Montreal, Quebec, Canada[1] which is credited with inventing the experimental peptide hormone CJC-1295.[2][3]
It employs 45 people, 90% of whom are in research and development.[citation needed][needs update]
References[edit]
- ^ "Conjuchem Biotechnologies Inc". Bloomberg Business. Retrieved 18 June 2015.
- ^ Teichman, Sam L.; Neale, Ann; Lawrence, Betty; Gagnon, Catherine; Castaigne, Jean-Paul; Frohman, Lawrence A. (2006). "Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults". The Journal of Clinical Endocrinology & Metabolism. 91 (3): 799–805. doi:10.1210/jc.2005-1536. ISSN 0021-972X. PMID 16352683.
- ^ "CJC-1295 or Modified GRF (1-29)". American Science Labs. 9 February 2015. Archived from the original on 18 June 2015. Retrieved 18 June 2015.
External links[edit]
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |